Quote from: ErinWDK on March 24, 2014, 10:23:21 AM
The main risk mentioned was stroke. This is based on statistics that women are more likely to have strokes than men.
Women usually have strokes at an advanced age,
when their estrogen levels are LOW! And as far as I know, women usually live longer than men. Furthermore, I have shown you evidence above indicating that stroke risk was not increased in women taking estrogen and that estrogen actually appeared to reduce cardiovascular incidences.
http://cardiovascres.oxfordjournals.org/content/69/4/777.full"There is an
abundance of scientific evidence for the protective effect of estrogen against atherosclerosis, such as short-term vasodilating effects as well as long-term vascular protective and anti-atherosclerotic effects [2]. Epidemiological evidence shows that pre-menopausal women have a reduced risk for mortality from cardiovascular diseases [3] and that women are at a lower risk for the development of heart failure [4] and have enhanced cognitive function and reduced neurodegeneration associated with Alzheimer's disease and stroke [5]. Further proof for the protective effect of female gender is the fact that post-menopausal women have a similar or even increased risk for cardiovascular disease compared to men [3] and have an increased risk for adverse outcome after myocardial infarction and acute coronary syndromes, despite similar treatment with thrombolysis and percutaneous interventions [6]. It was therefore postulated that estrogen replacement would be beneficial in preventing cardiovascular diseases in post-menopausal females."
"The cardioprotective effect of estrogen is further supported by the findings that ovariectomy caused a loss of cardioprotection, which was regained by chronic estrogen replacement therapy."
"The vascular protective effects of estrogen and their mechanisms are thus fairly well-established."
The increase in cardiovascular incidences in the Heart and Estrogen/Progestin Replacement Study (HERS) and the WHI (Womens's Health Initiative) study was due to the progestin as no such results were found in women only taking estrogen.
Steroids. 2003 Nov;68(10-13):831-6.
In vitro effects of progesterone and progestins on vascular cells."These pharmacological differences between progestins
are particularly relevant, in light of the first results of the
Women's Health Initiative (WHI) trial [7]. This is a randomized controlled
primary prevention trial, in which 16,608 postmenopausal women
aged 50–79 years with an intact uterus received
conjugated equine estrogens (CEE), plus MPA, or placebo.
The primary outcomes were nonfatal myocardial infarction and coronary
heart disease (CHD) death, with invasive breast cancer as
the primary adverse outcome. While the planned duration of
the treatment was 8.5 years, the CEE+MPA treatment arm
was stopped prematurely after 5.2 years, due to apparent increases
in cardiovascular events and breast cancer incidence
[7].
The evaluation of the CEE-alone treatment arm (women
without a uterus) is still ongoing, due to the absence of such
apparent increases in hazard. This is strongly suggestive
of a potentially harmful effect of the progestin used in the
study (MPA)."
CEE= conjugated equine estrogens
MPA= medroxyprogesterone acetate
Quote from: ErinWDK on March 24, 2014, 10:23:21 AMMy primary care doctor did note that taking one baby aspirin a day helps women partially reduce their stroke risk. I am on the aspirin regimen, so that helps.
Taking an Aspirin can cause ulcers over time. Estrogen is cardioprotective and if you are not genetically predisposed to heart problems (personal or family history), there is no reason to take Aspirin. It might do you more harm than good.
Quote from: ErinWDK on March 24, 2014, 10:23:21 AMThe very high E level women have during pregnancy is from E3 which is the weakest form of Estrogen.
From
http://cebp.aacrjournals.org/cgi/content-nw/full/12/5/452/T1 These levels were obtained just before labor/delivery, at the end of pregnancy which lasted on average, 38 weeks.
Mean estradiol levels (E2): 24,000 pg/ml, Range: from 800-75,000 pg/ml
Mean estrone levels (E1): 9,000 pg/ml, Range: from 600-61,000 pg/ml
Mean estriol levels (E3): 18,000 pg/ml, Range: 1,100-34,000 pg/ml
As you can see, the levels of all three estrogens are quite high, the mean levels of estradiol (the strongest estrogen) being the highest of the three, then estriol, then estrone. The range is highest for estradiol (the strongest estrogen), then estrone, then estriol (E3).
Quote from: ErinWDK on March 24, 2014, 10:23:21 AMNature does have a way of making things work.
What do you mean? Male prostate cancer patients were treated with bio-identical estrogen parenterally. Their estradiol levels on average were between 500-700 pg/ml and yet no cardiovascular or thromboembolic complications arose. I have pointed out these studies several times on here.
Quote from: ErinWDK on March 24, 2014, 10:23:21 AMMy doctors are NOT agreeing that generic Estradiol is safer than other forms.
And yet study after study show that bio-identical estradiol is safer than other forms, as it affects liver and clotting to a much lesser extent. The literature on it is quite vast and quite unequivocal. I have provided some of the evidence but there is much more.
Am J Obstet Gynecol. 1982 Nov 1;144(5):511-8.
Comparison of pharmacodynamic properties of various estrogen formulations."On a weight basis, piperazine estrone sulfate and micronized estradiol were equipotent for all responses. Conjugated estrogens suppressed FSH in a fashion equipotent to that of the other nonsynthetic estrogens; however, for all three hepatic parameters, the response was exaggerated twofold to threefold. The synthetic estrogens, diethylstilbestrol and ethinyl estradiol, were relatively more potent on a weight basis for every response and produced the most marked response (fourfold to eighteenfold in excess of their FSH suppression) for the hepatic parameters."
CLIMACTERIC 2005;8(Suppl 1):3–63
Pharmacology of estrogens and progestogens: influence of different routes of administration"EE is much more active than the natural estrogens,
because the 17a-ethinyl group prevents the oxidation
of the 17b-hydroxy group and is able – after
the oxidative formation of a very reactive intermediate
– to inhibit irreversibly cytochrome P450
enzymes, which are involved in the metabolism of
steroids. The potency of conjugated equine estrogens
(CEE) is considerably higher than that of
estradiol, particularly concerning the effect on the
hepatic production of certain serum parameters,
e.g. SHBG, corticosteroid-binding globulin
(CBG), thyroxine-binding globulin (TBG) and
angiotensinogen (Table 3)12–14."
J Clin Endocrinol Metab. 2003 Dec;88(12):5723-9.
Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people."The large differential effect of oral EE and oral E(2) indicates that the prothrombotic effect of EE is due to its molecular structure rather than to a first-pass liver effect (which they share). Moreover, these differences may explain why M-->F transsexuals treated with oral EE are exposed to a higher thrombotic risk than transsexuals treated with td E(2)."
"In conclusion, we have shown that treatment of MtF transsexuals with sex steroid hormones (CPA combined with E2 or EE) affects the hemostatic balance with a very pronounced difference in the effects of oral EE compared with the effects of both td E2 or oral E2. Oral EE induces a clinically relevant prothrombotic state."
JAMA Intern Med. 2014 Jan 1;174(1):25-31. doi: 10.1001/jamainternmed.2013.11074.
Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens."In an observational study of oral hormone therapy users, CEEs use was associated with a higher risk of incident venous thrombosis and possibly myocardial infarction than estradiol use. This risk differential was supported by biologic data. These findings need replication and suggest that various oral estrogen drugs may be associated with different levels of cardiovascular risk."
J Am Osteopath Assoc. 2011 Mar;111(3):153-64.
Bioidentical hormones: an evidence-based review for primary care providers"Randomized clinical trial data are sufficient to support the prescription of only estropipate, estradiol, and progesterone for the relief of menopausal symptoms. Estropipate is approved by the FDA for the management of menopausal symptoms. 17β-Estradiol is FDA approved for menopausal symptoms, may have cardioprotective effects, and may have fewer adverse effects on blood pressure than conjugated equine estrogens."
"Bioidentical hormones that are approved by the FDA may be preferred over standard hormone replacement because of their physiologic benefits and safety profile."
Quote from: ErinWDK on March 24, 2014, 10:23:21 AMThis can be argued, but the medical professionals I have a relationship with are not going to go there.
It cannot be argued. The difference in effect and risk has been shown between different estrogens. This is fact, not theory.